Search Results

Orum Therapeutics (“Orum”), a clinical-stage private biotechnology company pioneering Dual-Precision Targeted Protein Degradation (TPD² ™) and Targeted Protein Stabilization (TPS² ™), today announced that they have entered into a definitive agreement under which Bristol Myers Squibb has acquired Orum’s ORM-6151 program.

After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.

Orum Therapeutics, Inc. announced that it will present new preclinical data for its ORM-5029, ORM-6151, and PD-1-Cbl-b programs in three separate presentations at the American Association for Cancer Research Annual Meeting 2023 taking place April 14-19 in Orlando.

Orum Therapeutics today announced new preclinical data for three of Orum’s therapeutic programs: ORM-5029, which is a proprietary GSPT1 degrader conjugated to HER2-targeting antibody pertuzumab; ORM-6151, which delivers GSPT1 degrader to CD33+ tumors; and its new immuno-oncology program for a Cbl-b inhibitor (Cbl-bi) conjugated to anti-PD-1 antibody pembrolizumab.

Orum Therapeutics, a private clinical stage biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced that the Company’s leadership will participate in the following investor conferences.

Orum Therapeutics, a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced the presentation of preclinical data for ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader for acute myeloid leukemia (AML).

Orum Therapeutics today announced the formation of its scientific advisory board (SAB).

Orum Therapeutics today announced the appointment of David Main to the Company’s Board of Directors.

Orum Therapeutics, a biotechnology company pioneering the development of tumor-directed targeted protein degraders, announced that the Company’s leadership will participate in the following virtual conferences.